Donislecel
Brand names: Lantidra · Active ingredient: Donislecel
In short: LANTIDRA is an allogeneic pancreatic islet cellular therapy indicated for the treatment of adults with Type 1 diabetes who are unable to approach target HbA1c because of current repeated episodes of severe hypoglycemia despite intensive diabetes management and education. Use LANTIDRA in conjunction
What is Donislecel used for?
LANTIDRA is an allogeneic pancreatic islet cellular therapy indicated for the treatment of adults with Type 1 diabetes who are unable to approach target HbA1c because of current repeated episodes of severe hypoglycemia despite intensive diabetes management and education. Use LANTIDRA in conjunction with concomitant immunosuppression.
Limitations of Use
When considering the risks associated with the infusion procedure and long-term immunosuppression, there is no evidence to show a benefit of administration of LANTIDRA in patients whose diabetes is well-controlled with insulin therapy or patients with hypoglycemic unawareness who are able to prevent current repeated severe hypoglycemic events (neuroglycopenia requiring active intervention from a third party) using intensive diabetes management (including insulin, devices, and education).
Repeated intraportal islet infusions are not recommended in patients who have experienced prior portal thrombosis, unless the thrombosis was limited to second- or third-order portal vein branches.
There is no evidence to support the safe and effective use of LANTIDRA in patients with liver disease, renal failure, or who have received a renal transplant.
Donislecel dosage
For infusion into the hepatic portal vein only.
The recommended minimum dose is 5,000 EIN/kg for initial infusion and 4,500 EIN/kg for subsequent infusion in the same recipient. The maximum dose per infusion is dictated by the estimated tissue volume, which should not exceed 10 cc per infusion, and the total EIN present in the infusion bag (up to a maximum of 1 × 106 EIN per bag).
A second infusion may be performed if the patient does not achieve independence from exogenous insulin within one year of infusion or within one year after losing independence from exogenous insulin after a previous infusion. A third infusion may be performed using the same criteria as for the second infusion. There are no data regarding the effectiveness or safety for patients receiving more than three infusions.
Pre-procedural medications
Provide pre-procedural induction immunosuppression 30 – 360 minutes prior to LANTIDRA infusion. Include the following, at the discretion of the treating physician who is experienced with management of immunosuppression regimens for islet cell transplantation:
Non-depleting monoclonal anti-interleukin-2 (anti-IL-2) receptor antibody 120 minutes prior to islet infusion
Note: In patients who are sensitized (hypersensitivity with a past history of anaphylactic reaction) to non-depleting monoclonal anti-interleukin-2 (anti-IL-2) receptor antibody therapies, a polyclonal, T-cell-depleting antibody should be used instead.
Calcineurin inhibitor
Mammalian target of rapamycin (mTOR) inhibitor
Tumor necrosis factor (TNF) blocker.
Periprocedural antibiotic prophylaxis is recommended.
Keep LANTIDRA in the insulated container at 15°C to 25°C no longer than 48 hours from time of product release . Dispose of any product not used within 48 hours.
Do not irradiate.
Select and prepare units under the direction of a medical professional who is experienced in islet infusion (transplantation).
Use LANTIDRA as supplied and without further dilution.
Failure to follow these directions may result in damage and decreased viability of the islets.
Do not administer with leukodepleting filters.
To optimize viability, administer LANTIDRA as soon as possible after product release.
LANTIDRA should be administered only by interventional radiologists and surgeons with experience in islet cell transplantation under aseptic conditions in an interventional radiology or operating suite.
Perform all steps aseptically.
Use a 5 or 6 French angiographic catheter indicated for the delivery of drugs or other therapeutic fluids for infusion of LANTIDRA.
Catheter length: 65 cm or less.
Internal diameter: 0.97mm (0.038 inches) or greater.
Use only sheaths and introducers in combination with a catheter with the specified dimensions listed above to deliver LANTIDRA. …
How to take Donislecel — instructions & advice from the label
Advise the patient to read the FDA-approved patient labeling (Patient Information).
Prior to prescribing LANTIDRA discuss the following:
Procedural risks
Portal vein delivery
liver laceration and hematoma with severe, potentially life-threatening bleeding, which may require prolonged hospitalization and blood transfusions
liver injury from portal vein thrombosis and possible portal hypertension
Acute infusion reaction
symptoms may include fever, chills, fatigue, breathing problems, dizziness, nausea, vomiting, headache, or muscle aches
a minimum 24-hour stay in the hospital after the procedure will be required for monitoring
Immunosuppression requirements and risks
Treatment with immunosuppression
Is required long-term
If stopped would lead to loss of islet cell function and insulin production
Can interfere with response to immunizations and that they should avoid live vaccines
Increased risk of infection
Infections can be severe and life-threatening
Infections may require withdraw of immunosuppression
Development of lymphoma and other malignancies
Skin malignancies are most common
Lymphoma and some malignancies may require discontinuation of immunosuppression
Can interfere with …
Warnings & precautions
Do not take this medicine if: Do not administer LANTIDRA to patients who have concomitant diseases or conditions, including pregnancy, that contraindicate the procedure for LANTIDRA infusion or immunosuppression.
Concomitant use of immunosuppression is required to maintain islet cell viability. The use of immunosuppression in patients receiving LANTIDRA increases the risk of serious and potentially fatal adverse reactions. [Adverse Reactions (6.1)]
Patients receiving immunosuppressants are at increased risk of:
Bacterial, viral, fungal, and parasitic infections, including opportunistic infections.
Lymphomas and other malignancies, particularly of the skin.
Severe anemia, sometimes requiring transfusion.
Before Treatment
Vaccination: To mitigate the risk of infection, patients should receive recommended immunizations prior to treatment.
After Treatment
Administer PCP and CMV prophylaxis following administration of LANTIDRA.
Avoid live vaccination while receiving immunosuppression.
Monitor for fever and other signs of infection; initiate appropriate treatment early.
Clinically monitor for malignancy, including skin cancer.
Monitor hemoglobin/hematocrit and give blood products as indicated.
Considerations for discontinuation of immunosuppression
If a patient develops a life-threatening infection or cancer and treatment requires discontinuation of immunosuppression.
If a patient has been dependent on exogenous insulin for two years after their last infusion, then immunosuppression should be discontinued. However, the treatment team may consider continuation of immunosuppression if they determine that the patient has achieved target HbA1c without recurrent severe hypoglycemia in the presence of clinically relevant C-peptide, that provides a potential ongoing benefit that outweighs the risks of severe and potentially life-threatening effects of immunosuppression. …
Donislecel side effects
Ninety percent (90%) of subjects had at least one serious adverse reaction. The major causes were attributed to:
Infusion procedure
liver laceration/hematoma, hemorrhage, and intra-abdominal bleeding (13%)
elevation of portal pressure (7%)
Immunosuppression
Infection (87%)
Malignancy (37%)
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
The safety of LANTIDRA in subjects with type 1 diabetes and hypoglycemic unawareness was demonstrated in two clinical trials (Study 1, Study 2) involving a total of 30 subjects who received between one and three doses of LANTIDRA. Duration between first and second transplant was one month to 2.8 years and between second and third dose from 3 months to 7.8 years . Because of the variable duration of follow-up, number of infusions, and interval between infusions, adverse reactions were reported for the total duration for which each subject was followed. [Clinical Studies (14)] Subjects were followed for 0.3 to 14.5 years (mean 3 ± 3.7 years) after the first infusion.
Serious reactions were reported in 27 (90%) of subjects. …
About this medicine
LANTIDRA consists of a suspension of allogeneic pancreatic islets in buffered transplant medium containing sodium chloride, dextrose, minerals, amino acids, vitamins, and other compounds supplemented with HEPES (2-[4-(2-hydroxyethyl)piperazin-1-yl] ethanesulfonic acid; 10 mM final concentration) and human serum albumin (0.5% final concentration).
The active ingredient in LANTIDRA is allogeneic islets of Langerhans derived from a donor pancreas. Islets contain several types of endocrine (hormone-secreting) cells, including β-, α-, pancreatic peptide- (PP-), δ-, and ε-cells.
Each single-donor islet batch consists of two infusion bags connected to each other via a sterile connector. One LANTIDRA bag containing up to a maximum of 1 × 106 EIN in 400 ml of transplant media, and the second Rinse Bag containing 200 ml transplant media used to rinse the LANTIDRA bag and the infusion line. …
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 24610d9f-0c5a-4f55-93b3-d456300bfd5d. Read the full official label on DailyMed.
Related medicines
Atorvastatin Metformin Losartan Semaglutide Insulin Glargine Empagliflozin Glipizide Insulin Lispro